<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122369">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509612</url>
  </required_header>
  <id_info>
    <org_study_id>5</org_study_id>
    <nct_id>NCT01509612</nct_id>
  </id_info>
  <brief_title>Additive Homeopathy in Cancer Patients</brief_title>
  <acronym>HIC</acronym>
  <official_title>Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Lung Tumors With or Without &quot;add-on&quot; Homeopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the validity of their previous results in a randomized
      prospective, placebo-controlled, double-blind, multicenter controlled evaluation of
      questionnaires in patients with advanced malignant tumors. The investigators plan to compare
      the treatment outcome (quality of life and survival) in tumor patients, receiving standard
      or &quot;add-on&quot; homeopathic treatment.

      The null hypothesis is that &quot;add-on&quot; homeopathic treatment does not create a benefit for
      cancer patients. In addition the investigators evaluate survival time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EORTC-QLQ-C30 as well as a VAS scale for subjective well-being will be filled out by the
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Life quality</measure>
    <time_frame>7 years</time_frame>
    <description>Life quality is evaluated by using the results of the EORTC-QLQ-C30 questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>7 years</time_frame>
    <description>Survival is evaluated by assessing time in months from diagnosis until death</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>Additive homeopathy in cancer patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Additive homeopathic placebo globules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Additive classical homeopathy</intervention_name>
    <description>Homeopathic remedies every 2 to 3 months</description>
    <arm_group_label>Additive homeopathy in cancer patients</arm_group_label>
    <other_name>Classical homeopathic remedies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Homeopathic Placebo globules</intervention_name>
    <description>Homeopathic placebo globules every 2 to 3 months</description>
    <arm_group_label>Additive homeopathic placebo globules</arm_group_label>
    <other_name>Homeopathic Placebo globules looking identical to verum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Clinical diagnosis of advanced tumor stages of glioblastoma IV, metastasized sarcoma,
             as well as non small-cell lung carcinoma (NSCLC) IV.

        Exclusion Criteria:

          -  Pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Frass, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Frass, Prof. Dr.</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>4506</phone_ext>
    <email>michael.frass@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A 1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Frass, Prof. Dr.</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>4506</phone_ext>
      <email>michael.frass@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Michael Frass, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.homeopathicresearch.org</url>
    <description>Related info</description>
  </link>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 27, 2016</lastchanged_date>
  <firstreceived_date>January 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Michael Frass</investigator_full_name>
    <investigator_title>Principal Investigator, Prof. Dr., Director, Outpatient Unit Homeopathy in tumor patients</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>additive homeopathy</keyword>
  <keyword>patients with advanced malignant tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
